Excindogen

**Excindogen** is an investigational, FDA-repurposed **small molecule** immunotherapy being developed by **Vitalgenics** for **pancreatic ductal adenocarcinoma** and more broadly described by the company as a solid-tumor cancer therapy. Public company materials describe it as a non-toxic, orally described repurposed agent intended to inhibit multiple pathogenic biological sequences in pancreatic cancer, restore homeostasis in the pancreatic ductal microenvironment, reverse T-cell suppression or exhaustion, and enable antitumor adaptive immunity. Vitalgenics has also stated that preclinical work suggested effects on disease features such as **KRAS**-associated signaling, hypoxia, and stromal remodeling, and that the program received **FDA orphan drug designation** for pancreatic cancer. However, the precise molecular identity and direct validated target of Excindogen have not been clearly disclosed in the public domain.